Antisense gapmer oligonucleotides
CA 2506576 C · Owner: Westergaard, Majken · Inventors: Pedersen, Daniel Sejer; Christensen, Signe M.; Hansen, Henrik Frydenlund
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino- LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 18, 2003 and granted March 6, 2018. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 18, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 18, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.